Fennec Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Fennec Pharmaceuticals Inc. on September 9, 2019. The filing reports the appointment of a new senior executive officer. The company is incorporated in British Columbia, Canada, and its common shares trade on the Nasdaq Capital Market under the symbol "FENC".
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Shubh Goel as Chief Commercial Officer, effective September 23, 2019. Ms. Goel brings nearly 20 years of global commercial experience in oncology, having previously held leadership roles at Odonate Therapeutics, Celgene Corporation, and Bayer AG.
Compensation and Employment Terms
- Base Salary: $360,000 per year.
- Annual Bonus: Target of 40% of base salary, discretionary based on objectives set by the Board.
- Equity Grant: 175,000 stock options with a 10-year term. Vesting schedule includes one-third vesting one year after the grant date, with the remainder vesting monthly over the subsequent two years.
- Severance: In the event of termination without cause or for "good reason," Ms. Goel is entitled to 3 months of base salary (or 6 months if termination occurs after the second anniversary or due to a Change of Control), a pro-rata bonus, and acceleration of stock option vesting. These benefits are contingent upon the execution of a general release of claims.
Investor Verification Checklist
- Verify the commencement date of employment (September 23, 2019) and the execution of the full employment agreement (Exhibit 10.1).
- Review the specific performance objectives required to earn the 40% target bonus.
- Confirm the "Fair Market Value" used to determine the exercise price of the 175,000 stock options.
- Assess the impact of the new Chief Commercial Officer on the company's commercial strategy for its oncology pipeline.